Project Grant R01CA285370
Award Date
7/15/24
Completion Date
6/30/29
Dollars Obligated
$1.2M
Federal Agency
National Cancer Institute
Federal Grant Program
93.394
Assistance Type
Project Grant
Place of Performance
Charleston, SC 29425, USA
Similar Awards
This federal Project Grant award of $671,384 from the National Cancer Institute (NCI), under the Cancer Detection and Diagnosis Research program (CFDA 93.394), supports research to develop new biomarkers for cholangiocarcinoma (CCA) based on changes in glycosylation patterns observed in CCA tissue and serum samples. The primary awardee, the Medical University of South Carolina (MUSC), will collaborate with sub-awardees Mayo Clinic and the University of Texas Southwestern Medical Center to...
This $563,233 federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) supports research at the Medical University of South Carolina (MUSC) to investigate how the sphingosine kinase 2 (SPHK2)/sphingosine-1-phosphate (S1P) axis regulates the immunosuppressive phenotype of myeloid-derived suppressor cells (MDSCs) in the tumor microenvironment. The key objectives are to: 1) determine how SPHK2-mediated S1P induces the MDSC suppressive phenotype, 2)...
This $363,177 federal Project Grant award from the National Institute of General Medical Sciences (NIGMS) Biomedical Research and Research Training Program (CFDA 93.859) supports the development of enabling biotechnology tools to advance fundamental studies of glycosylation. Key products and services to be delivered over the 5-year project period include: Generation of fast, low-volume assays to quantify enzyme activity in complex systems, characterize monovalent and multivalent interactions...
This federal Project Grant award, valued at $342,342.00, was provided by the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training Program (CFDA 93.859). The grant supports a research program focused on developing and applying chemistry-enabled approaches to address critical questions in glycoscience. The key products and services to be delivered include: a) Generating and applying cell/tissue-selective reporters and inhibitors of...
This $427,095 Project Grant award from the National Cancer Institute (NCI) under the Cancer Detection and Diagnosis Research program (CFDA 93.394) supports the development of a novel microfluidic droplet-based platform (MDP) technology to generate and analyze a 3D biomimetic multicellular immunogenic tumor model. The goal is to establish multiple levels of hypoxia within the tumor-chip, investigate spatiotemporal interaction between the tumor microenvironment and cancer-immune cells during...
The National Cancer Institute (CFDA 93.396 - Cancer Biology Research) awarded Loyola University of Chicago a $461,844 project grant titled "Hyperpolarized 13C Metabolic Imaging of Tumorigenesis in the Liver". The objective is to use novel hyperpolarized 13C probes to image glycolysis, a critical pathway in hepatocellular carcinoma (HCC) development, and establish in vivo imaging biomarkers to assess altered liver metabolism during HCC progression. The project aims to synthesize a...
This Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) provides $678,228 to The General Hospital Corporation (doing business as Massachusetts General Hospital) to develop GLISCAN, a multi-analyte, multi-mutation blood-based assay for rapid, sensitive molecular subtyping of gliomas. The project aims to optimize, verify, and validate the GLISCAN assay, which quantifies tumor mutations (TERT C228T/C250T, EGFRVIII, IDH1.R132H) and a...
This $382,500 Project Grant award from the National Institute of General Medical Sciences (NIGMS) Biomedical Research and Research Training Program (CFDA 93.859) supports research to investigate how spatial organization of glycan ligands influences glycobiology processes on the cell membrane. The project aims to integrate microscopy, spectroscopy, and computational modeling to unravel the microscopic binding mechanisms of lectin-glycan interactions. It will also explore approaches to control...
This Project Grant award from the National Cancer Institute (CFDA 93.396 Cancer Biology Research) provides $335,944 to Vanderbilt University to further develop, refine, and validate their emerging free-solution assay (FSA) technology and compensated interferometric reader (CIR). The goal is to create a label-free, solution-phase, ultra-sensitive, enzyme-free technology compatible with a wide range of biological matrices. This novel platform is designed to support critical cancer research...
This $417,400 Project Grant award from the National Institute of General Medical Sciences (NIGMS) Biomedical Research and Research Training Program (CFDA 93.859) supports the development and advancement of mass spectrometry imaging (MSI) tools to enable more accurate and comprehensive chemical characterization of the glycome (the complete repertoire of cell carbohydrates) at tissue functional unit and cellular resolutions. The research aims to overcome current limitations in glycome imaging by...